Evidence map›Paper›PMID 32228674›Full record

ArticleTrials2020

Sample size calculation in randomised phase II selection trials using a margin of practical equivalence.

Hakim-Moulay Dehbi, Allan Hackshaw

Abstract read
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Designing a need-based program for relieving psychological distress of family caregivers of leukemia patients: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hakim-Moulay DehbiComprehensive Clinical Trials Unit at University College London (UCL), 90 High Holborn, London, WC1V 6LJ, UK. h.dehbi@ucl.ac.uk.
Allan HackshawCancer Research UK & UCL Cancer Trials Centre, 90 Tottenham Court Road, London, W1T 4TJ, UK.

Funding

Cancer Research UK C444/A15953
6 · The paper itself

Abstract

backgroundIn rare cancers or subtypes of common cancers, a comparison of multiple promising treatments may be required. The selected treatment can then be assessed against the standard of care (if it exists) or used as a backbone for combinations with new, possibly targeted, agents. There could be different experimental therapies or different doses of the same therapy, and either can be done in combination with standard treatments. A 'pick-the-winner' design is often used, which focuses on efficacy to select the most promising treatment. However, a treatment with a slightly lower efficacy compared to another treatment may actually be preferred if it has a better toxicity or quality of life profile, is easier to administer, or cheaper.

methodsBy pre-defining a margin of practical equivalence in order to calculate the sample size, a more flexible assessment can be made of whether the treatments have very different effects or are sufficiently close so that other factors can be used to choose between them. Using exact binomial probabilities, we calculated the sample size for two- and three-arm randomised selection trials including a margin of practical equivalence with a variety of input parameters.

resultsWe explain conceptually the margin of practical equivalence in this paper, and provide a free user-friendly web application to calculate the required sample size for a variety of input parameters.

conclusionThe web application should help promote the randomised selection design with a margin of practical equivalence, which provides greater flexibility than the 'pick-the-winner' approach in assessing the results of selection trials.

Indexed as

Sample SizeTherapeutic EquivalencyClinical Trials, Phase II as TopicHumansNeoplasmsRandomized Controlled Trials as TopicResearch DesignRandomised trialRare cancersSelection design

Identifiers

PMID32228674
PMCPMC7106856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.